External Expert, Management to Present on IC/BPS and Clinical Development Program
VANCOUVER, British Columbia, Jan. 26, 2018 (GLOBE NEWSWIRE) — Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, today announced that it will host an analyst and investor event in New York City on Friday, February 9 from 10:00am to 12:00pm EST, followed by an open lunch.
The event will feature a presentation from Dr. Philip Hanno, MD, MPH, clinical professor of urology at the Stanford University School of Medicine and co-chair of the Medical Advisory Board of the Interstitial Cystitis Association (ICA). Dr. Hanno is an expert in the treatment of urologic chronic pain conditions including interstitial cystitis/bladder pain syndrome (IC/BPS).
Aquinox will provide an update on its clinical development program for rosiptor (AQX-1125), including the LEADERSHIP 301 clinical trial studying rosiptor in subjects with IC/BPS. The commercial environment in IC/BPS will also be discussed.
Aquinox presenters will include:
- David Main, President and Chief Executive Officer
- Barbara Troupin, MD, MBA, Chief Medical Officer and Vice President of Clinical Development and Regulatory Affairs
- Abigail Jenkins, Chief Commercial Officer and US Business Head
Institutional investors and sell-side analysts may register to attend the event in person by sending an email to firstname.lastname@example.org. A live webcast of the presentations will be available at https://www.webcaster4.com/Webcast/Page/359/24233 and from the “Events & Presentations” page of Aquinox’s website at http://investor.aqxpharma.com/events.cfm. It is recommended that participants dial in 15 minutes early to minimize any delay in joining the webcast.
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics for chronic urological conditions marked by inflammation and pain. Aquinox’s lead drug candidate, rosiptor (AQX-1125), is a first-in-class, once-daily, oral treatment with a novel mechanism of action, activating SHIP1 (SH2-containing inositol-5′-phosphatase 1), an enzyme that serves to down-regulate inflammation through its role in the PI3K signaling pathway. Rosiptor is in Phase 3 development for the treatment of patients with interstitial cystitis/bladder pain syndrome (IC/BPS), a debilitating condition marked by chronic bladder pain and urinary symptoms, for which there are currently few FDA approved and/or effective treatment options. Aquinox is focused on leveraging its library of novel compounds that activate SHIP1 to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. For more information, please visit www.aqxpharma.com.